Spyre Therapeutics, Inc.

VANGUARD GROUP INC SYRE

Report date

6/30/2023

Quarter

2023 Q2

Filed

8/14/2023

Shares

648,053

Value ($000)

292

Weight

0.0%

2019 Q4 - 2023 Q2 (15 filings)

Shares History

History scope: non-option holdings only (PUT/CALL rows excluded).

All 13F Holders	Filing date	Value ($000s)	% of Holdings	Shares	Reporting period
2023 Q2	8/14/2023	292	0.0%	648,053	6/30/2023
2023 Q1	7/14/2023	579	0.0%	1,997,597	3/31/2023
2022 Q4	2/10/2023	899	0.0%	1,997,597	12/31/2022
2022 Q3	11/14/2022	993	0.0%	1,887,396	9/30/2022
2022 Q2	8/12/2022	984	0.0%	1,948,009	6/30/2022
2022 Q1	5/13/2022	4,869	0.0%	2,117,323	3/31/2022
2021 Q4	2/14/2022	10,073	0.0%	2,120,625	12/31/2021
2021 Q3	11/12/2021	16,765	0.0%	2,108,760	9/30/2021
2021 Q2	8/13/2021	14,596	0.0%	2,097,166	6/30/2021
2021 Q1	5/14/2021	17,219	0.0%	2,174,062	3/31/2021
2020 Q4	2/12/2021	15,356	0.0%	1,951,224	12/31/2020
2020 Q3	11/16/2020	13,112	0.0%	1,849,454	9/30/2020
2020 Q2	8/14/2020	17,071	0.0%	1,845,496	6/30/2020
2020 Q1	5/15/2020	5,518	0.0%	1,184,306	3/31/2020
2019 Q4	2/14/2020	9,016	0.0%	1,180,164	12/31/2019